Pancreatic adenocarcinoma is the fourth leading cause of adult cancer mortality in the United States. The five-year survival rate continues at 1-3%. At the time of diagnosis, most pancreatic cancer patients present with advanced and metastatic disease. Although a genetic profile for pancreatic caner is emerging, it is still unknown how these genetic alterations elicit the unique phenotypes and clinical course of pancreatic cancer. The underlying mechanisms, by which pancreatic epithelial cells become tumorigenic, invasive and metastatic, remain to be elucidated. The advance in understanding of the molecular basis of pancreatic cancer is hindered in part due to the lack of normal human pancreatic ductal epithelial cells for analyzing the role of genetic alterations in tumorigenesis and metastasis, and experimental animal models that recapitulate the molecular pathogenesis and tumor biology of this disease. Therefore, the long-term objective of the proposed research is study the molecular basis of pancreatic tumorigenesis and metastasis using an E6E7-immortalized human pancreatic ductal epithelial (HPDE/E6E7) cells that carry the signature genetic alterations in this disease, and determine the phenotypes induced by these genetic alterations using an orthotopic mouse model. The recent findings show that: (1) mutated K-ras4B (G12V) transformed HPDE/E6E7 and induced weak tumorigenicity in orthotopic mouse model; (2) the K-ras downstream target genes were identified; (3) the mutant IkappaBalpha (S32, 36A) mediated inhibition of constitutive NF-kappaB activation suppressed liver metastasis of pancreas cancer cells in an orthotopic nude mouse model; (4) overexpression of Smad4 inhibits tumorigenesis of pancreatic cancer cell lines. The hypothesis, activation of K-ras and NF-kappaB, or inactivation of Smad4 induces tumorigenic or metastatic phenotype by altering the expression of their downstream target genes in immortalized human pancreatic ductal epithelial cells, will be tested.
The specific aims are: (1) Study the mechanism of K-ras induced oncogenic transformation of HPDE/E6E7 cells (2) Determine the function of constitutively activated NF-kappaB in induction of metastasis. (3) Determine the role of Smad4 in initiating tumorigenic and metastatic phenotypes in HPDE/E6E7 cells. Generation of various cell lines that carry the signature mutation of pancreatic cancer should permit the identification of the genetic alterations required in concert to induce tumorigenic and metastatic phenotype of this disease. Furthermore, mechanisms underlying tumor progression, including genomic instability and alterations in signal cascades associated with these pancreatic cancer signature mutations can be analyzed in a relevant in vivo and in vitro context using molecular and biochemical methods. A better understanding of the mechanisms of genetic alterations in induction of tumorigenic and metastatic phenotypes will provide a basis for developing early detection and effective treatment strategies for pancreatic cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA109405-03
Application #
7240563
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Ault, Grace S
Project Start
2005-09-01
Project End
2010-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
3
Fiscal Year
2007
Total Cost
$183,474
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Zhuang, Zhuonan; Li, Hao; Lee, Harold et al. (2017) NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-?B activation. Cancer Lett 411:44-56
Chiao, Paul J; Ling, Jianhua; Fu, Jie et al. (2017) Inhibition of Pancreatic Cancer by RhIL1RA-Response. Clin Cancer Res 23:3224
Ju, Huai-Qiang; Ying, Haoqiang; Tian, Tian et al. (2017) Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 8:14437
Zhuang, Zhuonan; Ju, Huai-Qiang; Aguilar, Mitzi et al. (2016) IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-?B Activation. Clin Cancer Res 22:1432-44
Ju, Huai-Qiang; Gocho, Takeshi; Aguilar, Mitzi et al. (2015) Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation. Mol Cancer Ther 14:788-98
Chang, Zhe; Ju, Huaiqiang; Ling, Jianhua et al. (2014) Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis. PLoS One 9:e101452
Chang, Zhe; Li, Zhongkui; Wang, Xiaoyang et al. (2013) Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells. Clin Cancer Res 19:549-59
Ling, Jianhua; Kang, Ya'an; Zhao, Ruiying et al. (2012) KrasG12D-induced IKK2/?/NF-?B activation by IL-1? and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 21:105-20
Melisi, Davide; Xia, Qianghua; Paradiso, Genni et al. (2011) Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J Natl Cancer Inst 103:1190-204
Carbone, Carmine; Moccia, Tania; Zhu, Cihui et al. (2011) Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. Clin Cancer Res 17:5822-32

Showing the most recent 10 out of 14 publications